Logo image of INMB

INMUNE BIO INC (INMB) Stock Overview

NASDAQ:INMB - US45782T1051 - Common Stock

2.03 USD
-0.06 (-2.87%)
Last: 8/29/2025, 8:00:02 PM
2.07 USD
+0.04 (+1.97%)
After Hours: 8/29/2025, 8:00:02 PM

INMB Key Statistics, Chart & Performance

Key Statistics
52 Week High11.64
52 Week Low1.89
Market Cap53.98M
Shares26.59M
Float20.01M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-2.48
PEN/A
Fwd PEN/A
Earnings (Next)10-29 2025-10-29
IPO02-04 2019-02-04
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


INMB short term performance overview.The bars show the price performance of INMB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

INMB long term performance overview.The bars show the price performance of INMB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of INMB is 2.03 USD. In the past month the price decreased by -20.7%. In the past year, price decreased by -69.34%.

INMUNE BIO INC / INMB Daily stock chart

INMB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About INMB

Company Profile

INMB logo image INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 22 full-time employees. The company went IPO on 2019-02-04. The firm has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.

Company Info

INMUNE BIO INC

225 Ne Mizner Blvd, Suite 640

Boca Raton FLORIDA 92037 US

CEO: Raymond J. Tesi

Employees: 18

INMB Company Website

INMB Investor Relations

Phone: 18589643720

INMUNE BIO INC / INMB FAQ

What is the stock price of INMUNE BIO INC today?

The current stock price of INMB is 2.03 USD. The price decreased by -2.87% in the last trading session.


What is the ticker symbol for INMUNE BIO INC stock?

The exchange symbol of INMUNE BIO INC is INMB and it is listed on the Nasdaq exchange.


On which exchange is INMB stock listed?

INMB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for INMUNE BIO INC stock?

13 analysts have analysed INMB and the average price target is 8.57 USD. This implies a price increase of 322.07% is expected in the next year compared to the current price of 2.03. Check the INMUNE BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is INMUNE BIO INC worth?

INMUNE BIO INC (INMB) has a market capitalization of 53.98M USD. This makes INMB a Micro Cap stock.


How many employees does INMUNE BIO INC have?

INMUNE BIO INC (INMB) currently has 18 employees.


Is INMUNE BIO INC (INMB) expected to grow?

The Revenue of INMUNE BIO INC (INMB) is expected to grow by 217.43% in the next year. Check the estimates tab for more information on the INMB EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy INMUNE BIO INC (INMB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does INMUNE BIO INC (INMB) stock pay dividends?

INMB does not pay a dividend.


When does INMUNE BIO INC (INMB) report earnings?

INMUNE BIO INC (INMB) will report earnings on 2025-10-29.


What is the Price/Earnings (PE) ratio of INMUNE BIO INC (INMB)?

INMUNE BIO INC (INMB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.48).


What is the Short Interest ratio of INMUNE BIO INC (INMB) stock?

The outstanding short interest for INMUNE BIO INC (INMB) is 29.9% of its float. Check the ownership tab for more information on the INMB short interest.


INMB Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

INMB Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to INMB. While INMB seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

INMB Financial Highlights

Over the last trailing twelve months INMB reported a non-GAAP Earnings per Share(EPS) of -2.48. The EPS decreased by -20.39% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -147.05%
ROE -191.97%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-110%
Sales Q2Q%N/A
EPS 1Y (TTM)-20.39%
Revenue 1Y (TTM)-39.02%

INMB Forecast & Estimates

13 analysts have analysed INMB and the average price target is 8.57 USD. This implies a price increase of 322.07% is expected in the next year compared to the current price of 2.03.

For the next year, analysts expect an EPS growth of 29.06% and a revenue growth 217.43% for INMB


Analysts
Analysts76.92
Price Target8.57 (322.17%)
EPS Next Y29.06%
Revenue Next Year217.43%

INMB Ownership

Ownership
Inst Owners27.99%
Ins Owners17.52%
Short Float %29.9%
Short Ratio1.43